Genomma Lab InternacionalB de CV (FRA:GEKA) Other Current Liabilities: €110.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:GEKA Genomma Lab Internacional SAB de CV FRA:GEKA
66 GF Score
Price €0.74
GF Value €0.85
! 4 Warning Signs
View Full Analysis

What is Genomma Lab InternacionalB de CV Other Current Liabilities?

Genomma Lab InternacionalB de CV FRA:GEKA -0.68% 66 Other Current Liabilities is €110.0 Mil as of Mar. 2026. GuruFocus rates FRA:GEKA with a GF Score™ of 66/100 and a GF Value™ of €0.85. The stock has 4 warning signs investors should review.

Genomma Lab InternacionalB de CV's other current liabilities for the quarter that ended in Mar. 2026 was €110.0 Mil.

Genomma Lab InternacionalB de CV's quarterly other current liabilities increased from Sep. 2025 (€121.2 Mil) to Dec. 2025 (€123.5 Mil) but then declined from Dec. 2025 (€123.5 Mil) to Mar. 2026 (€110.0 Mil).

Genomma Lab InternacionalB de CV's annual other current liabilities increased from Dec. 2023 (€56.3 Mil) to Dec. 2024 (€71.4 Mil) and increased from Dec. 2024 (€71.4 Mil) to Dec. 2025 (€123.5 Mil).

Genomma Lab InternacionalB de CV Other Current Liabilities Related Terms

Genomma Lab InternacionalB de CV Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Genomma Lab InternacionalB de CV's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomma Lab InternacionalB de CV Other Current Liabilities Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.99 37.82 56.28 71.38 123.45

Genomma Lab InternacionalB de CV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 148.24 138.19 121.18 123.45 110.02
FRA:GEKA
66GF Score
Genomma Lab Internacional SAB de CV FRA:GEKA
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomma Lab InternacionalB de CV Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €110.0 Mil mean?
Genomma Lab InternacionalB de CV (FRA:GEKA) has a Other Current Liabilities of €110.0 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Genomma Lab InternacionalB de CV.
Is Genomma Lab InternacionalB de CV's Other Current Liabilities too high?
Genomma Lab InternacionalB de CV's current Other Current Liabilities is €110.0 Mil. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Other Current Liabilities compare to ZTS and UTHR?
Genomma Lab InternacionalB de CV's Other Current Liabilities of €110.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Genomma Lab InternacionalB de CV. Genomma Lab InternacionalB de CV's current Other Current Liabilities is €110.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Genomma Lab InternacionalB de CV (FRA:GEKA) has a current Other Current Liabilities of €110.0 Mil. The stock's GF Value™ is €0.85, compared to a current price of €0.74 — trading 13.5% below its estimated fair value. The current Other Current Liabilities is €110.0 Mil. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (FRA:GEKA), the current Other Current Liabilities is €110.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomma Lab InternacionalB de CV (FRA:GEKA) Overvalued in 2026?

Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued. The current stock price of €0.74 is trading 13.5% below its estimated GF Value™ of €0.85.

Key valuation signals for FRA:GEKA:

  • Other Current Liabilities: €110.0 Mil
  • GF Value™: €0.85 vs. price of €0.74 (13.5% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the FRA:GEKA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomma Lab InternacionalB de CV Business Description

Other Exchanges GNMLF:USALABB:Mexico
Address Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score

Get the complete analysis for FRA:GEKA

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.74
Price
€0.85
GF Value